	US 12,065,492 B2
	Anti-B7-H6 antibody, fusion proteins, and methods of using the same
Charles L. Sentman, Grantham, NH (US); and Tong Zhang, Beijing (CN)
Assigned to THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed by THE TRUSTEES OF DARTMOUTH COLLEGE, Hanover, NH (US)
Filed on Jan. 12, 2021, as Appl. No. 17/146,814.
Application 17/146,814 is a division of application No. 15/784,342, filed on Oct. 16, 2017, granted, now 11,034,766.
Application 15/784,342 is a division of application No. 14/399,835, granted, now 9,790,278, issued on Oct. 17, 2017, previously published as PCT/US2013/039812, filed on May 7, 2013.
Claims priority of provisional application 61/705,227, filed on Sep. 25, 2012.
Claims priority of provisional application 61/643,456, filed on May 7, 2012.
Prior Publication US 2021/0206858 A1, Jul. 8, 2021
Int. Cl. A61P 35/00 (2006.01); A61K 39/395 (2006.01); C07K 14/705 (2006.01); C07K 14/725 (2006.01); C07K 16/28 (2006.01)

CPC C07K 16/2827 (2013.01) [A61K 39/3955 (2013.01); C07K 14/7051 (2013.01); C07K 14/70521 (2013.01); C07K 16/2809 (2013.01); C07K 2317/24 (2013.01); C07K 2317/31 (2013.01); C07K 2317/622 (2013.01); C07K 2319/00 (2013.01); C07K 2319/33 (2013.01)]

11 Claims

1. A method for treating a subject having B7-H6 expressing cancer cells, wherein said cancer cells are selected from myeloid leukemia, acute nonlymphocytic leukemia, T-cell acute lymphoblastic leukemia, T-cell lymphoma and B-cell lymphoma cells, by killing or inhibiting the growth of said cancer cells expressing B7-H6, by administering an isolated antibody, or antigen binding fragment of the antibody, which specifically binds to B7 homolog 6 (B7-H6) comprising:

(a) a heavy chain variable region comprising,

(i) a CDR1 of SEQ ID NO: 5,

(ii) a CDR2 of SEQ ID NO: 6, and

(iii) a CDR3 of SEQ ID NO: 7; and

(b) a light chain variable region comprising,

(i) a CDR1 of SEQ ID NO: 8,

(ii) a CDR2 of SEQ ID NO: 9, and

(iii) a CDR3 of SEQ ID NO: 10.